Table 4. Rate of tumour response to treatment with somatostatin analogues in 106 pts with G1-G2 NET.
| Tumour Response | |
| Total patients | n° (%) |
| Complete Response | 2 (2.0) |
| Partial Response | 10 (9.0) |
| Stable Disease | 61 (58) |
| Progression | 33 (31) |
| G1 NET | |
| Complete Response | 1 (2.0) |
| Partial Response | 3 (6.0) |
| Stable Disease | 33 (67) |
| Progression | 12 (25) |
| G2 NET | |
| Complete Response | 1 (2.0) |
| Partial Response | 7 (12) |
| Stable Disease | 28 (49) |
| Progression | 21 (37) |
| Patients with Lung – Thymus NET | |
| Complete Response | 0 |
| Partial Response | 1 (6.0) |
| Stable Disease | 11 (61) |
| Progression | 6 (33) |
| Patients with Pancreas NET | |
| Complete Response | 0 |
| Partial Response | 6 (12) |
| Stable Disease | 30 (61) |
| Progression | 13 (27) |
| Patients with Gastro-Intestinal NET | |
| Complete Response | 2 (7.0) |
| Partial Response | 2 (7.0) |
| Stable Disease | 16 (53) |
| Progression | 10 (33) |
| Patients with unknown primary NET | |
| Complete Response | 0 |
| Partial Response | 1 (11) |
| Stable Disease | 4 (44) |
| Progression | 4 (44) |
| Patients with loco-regional disease | |
| Complete Response | 1 (2.0) |
| Partial Response | 5 (10) |
| Stable Disease | 37 (72) |
| Progression | 8 (16) |
| Patients with distant metastases | |
| Complete Response | 1 (1.8) |
| Partial Response | 5 (9.2) |
| Stable Disease | 24 (44) |
| Progression | 25 (45) |
NET: neuroendocrine tumour